Real-world assessment of sparsentan’s drug safety framework
Real-world assessment of sparsentan’s drug safety framework
About this item
Full title
Author / Creator
Publisher
England: Taylor & Francis Group
Journal title
Language
English
Formats
Publication information
Publisher
England: Taylor & Francis Group
Subjects
More information
Scope and Contents
Contents
Sparsentan has been approved for reducing proteinuria in adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, yet comprehensive studies evaluating its drug safety framework are lacking.
Adverse event (AE) reports following the market release of sparsentan were collected from the U.S. Food and Drug Administrati...
Alternative Titles
Full title
Real-world assessment of sparsentan’s drug safety framework
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_99b26dfc93e740c3bd3609cd89fe4253
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_99b26dfc93e740c3bd3609cd89fe4253
Other Identifiers
ISSN
0886-022X,1525-6049
E-ISSN
1525-6049
DOI
10.1080/0886022X.2025.2461668
